⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3928808 | 1.00 | — | — | |
| SCHEMBL2896865 | 1.00 | — | — | |
| SCHEMBL17798814 | 1.00 | — | — | |
| SCHEMBL4559444 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL4062230 | 0.98 | GAA (0.37) | — | |
| Methane SCHEMBL29180228 | 0.98 | GAA (0.33) | — | |
| Hydrochloric Acid SCHEMBL5457644 | 0.98 | GAA (0.37) | — | |
| SCHEMBL24862658 | 0.78 | — | — | |
| SCHEMBL532330 | 0.77 | — | — | |
| SCHEMBL9203898 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179496-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2025-06-05 | — | — | US | disclosed |
| US-20250099594-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2025-03-27 | — | — | US | disclosed |
| CN-118460536-A | Targeting composition | 阿布特斯生物制药公司 | 2024-08-09 | — | — | CN | disclosed |
| US-20240245784-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2024-07-25 | — | — | US | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| US-12043833-B2 | Targeted compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-07-23 | — | — | US | disclosed |
| CN-110741087-B | Targeting composition | 阿布特斯生物制药公司 | 2024-05-14 | — | — | CN | disclosed |
| US-11896672-B2 | Targeted nucleic acid conjugate compositions | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-02-13 | — | — | US | disclosed |
| US-20230110295-A1 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (US) | 2023-04-13 | — | — | US | disclosed |
| WO-2019051257-A2 | METHODS FOR TREATING HEPATITIS B INFECTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019051257-A2 | METHODS FOR TREATING HEPATITIS B INFECTIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2019-03-14 | — | — | WO | disclosed |
| EP-3443092-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | Arbutus Biopharma Corporation (CA) | 2019-02-20 | — | — | EP | disclosed |
| WO-2018191278-A2 | TARGETED COMPOSITIONS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-10-18 | — | — | WO | disclosed |
| US-20170305907-A1 | METHODS OF PRODUCING HETEROPOLYCYCLES VIA BIS-EPOXIDATION | LIGHTNER DEREK ALTON (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170305907-A1 | METHODS OF PRODUCING HETEROPOLYCYCLES VIA BIS-EPOXIDATION | LIGHTNER DEREK ALTON (US) | 2017-10-26 | — | — | US | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
| WO-2017177326-A1 | TARGETED NUCLEIC ACID CONJUGATE COMPOSITIONS | PROTIVA BIOTHERAPEUTICS, INC. (CA) | 2017-10-19 | — | — | WO | disclosed |
| US-7632829-B2 | Diazepan derivatives | HOFFMANN-LA ROCHE INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070249589-A1 | Novel diazepan derivatives | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2007-10-25 | — | — | US | disclosed |